Skip to main content

AMCP Nexus 2025 Posters Main banner

Oncology

Oncology

Type here to filter the list

(291) A development of monocarboxylate transporter 4 inhibitor/docetaxel-loaded smart layer-by-layer nanoparticles for prostate cancer therapy
(292) Real-World patterns of intravenous immunoglobulin (IVIG) and antimicrobial use in members with multiple myeloma treated with chimeric antigen receptor T-cell (CAR T) or bispecific antibody (BsAbs) therapies
(293) Real-World Clinical Outcomes and Healthcare Resource Utilization with Covalent BTK Inhibitors in CLL/SLL (2020–2025): A Systematic Review
(294) Healthcare Resource Utilization and Costs Among Patients With vs Without Biomarker Testing in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis of Horizon BCBSNJ Members
(295) Machine Learning Performance in Diagnosis and Treatment of Head and Neck and Esophageal Cancers: A Scoping Review
(296) Cost-effectiveness of xofigo in bone-metastatic castration-resistant prostate cancer: a markov model analysis
(297) Assessing the Cost-Utility of Predictive Biomarkers in Oncology Treatment Compared to Traditional Approaches
(298) Assessing tumor volume: a scoping review of measurement methods and clinical utility in head and neck and lung cancers
(299) Patient-reported outcomes evaluating physical functioning and symptoms in patients with pretreated human epidermal growth factor receptor 2-mutant advanced non-small cell lung cancer - results from the Beamion LUNG-1 trial
(300) Economic burden of recurrence in early-stage hepatocellular carcinoma (HCC) treated with curative intent: A retrospective analysis of SEER-Medicare data
(301) Zongertinib in patients with pretreated human epidermal growth factor receptor 2-mutant advanced non–small cell lung cancer: Beamion LUNG-1
(302) Managed care approaches to bispecific antibodies (BsAbs) in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL): AMCP Market Insights Program
(303) Real-world (RW) sequential regorafenib and trifluridine/tipiracil + bevacizumab (BEV) treatment for metastatic colorectal cancer (mCRC) in the United States (US) community oncology setting A post-hoc analysis of SEQRT2 study
(304) Real-world analysis of healthcare resource utilization and costs among patients with high-risk non–muscle-invasive bladder cancer with papillary-only disease who are unresponsive to Bacillus Calmette-Guérin treatment using SEER-Medicare data
(305) Real-world analysis of treatment patterns and disease recurrence among patients with high-risk non–muscle-invasive bladder cancer with papillary-only disease who are unresponsive to Bacillus Calmette-Guérin therapy using SEER-Medicare data
(306) Life-year and quality-adjusted life-year results from a United States cost-effectiveness model for belantamab mafodotin, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma
(307) Epidemiology and diagnostic landscape for gastroesophageal adenocarcinomas with a HER2 focus
(308) A survey of healthcare decision maker (HCDM) formulary management perspectives in crowded oncologic markets: a focus on advanced non-small cell lung cancer (aNSCLC) and relapsed/refractory multiple myeloma (RRMM)
(309) Systematic Literature Review of Healthcare Resource Use (HCRU), Costs and Health-Related Quality of Life (HRQoL) for Brexucabtagene autoleucel in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) and Precursor B-cell lymphoblastic leukemia (B-ALL)
(310) Multicomponent interventions to improve adherence and symptom management in patients receiving CDK4/6 inhibitors: A real-world U.S. evidence review
(311) Belantamab Mafodotin Individual Patient Dosing in Patients With Relapsed/Refractory Multiple Myeloma Treated in the Phase 3 DREAMM-7 and DREAMM-8 Clinical Trials
(312) Leveraging Causal Analysis to Identify Trastuzumab Biosimilar Adoption Drivers and Patient Outcomes: A Real-World Claims Data Analysis
(314) Recent Real-World Treatment Patterns of Advanced Melanoma in the United States
(315) Economic burden of neutropenia among patients treated for HR+/HER2- and triple-negative metastatic breast cancer in the United States: a retrospective claims analysis
(316) Cost-effectiveness of sotorasib vs. adagrasib in KRAS G12C-mutated previously treated non-small cell lung cancer (NSCLC): An economic evaluation on Phase 3 trial results
(317) Similarities of oral oncology drugs excluded by large pharmacy benefit managers (PBMs)
(319) Cost-Inefficiency of High-Dose Opioids Therapy in Disease-Free Cancer Survivors: A Real-World, U.S. Payer-Perspective Decision-Tree Analysis
(320) Trends in Industry Payments to U.S. Oncologists: Insights from the 2014 –2023 CMS Open Payments Datasets
(321) Total cost of care (TCOC) and adverse effects (AEs) assessment of bispecific T cell engagers (BiTEs) and Chimeric Antigen Receptor T-Cell (CAR T) therapies for relapsed refractory follicular lymphoma (RRFL)
(322) Healthcare resource utilization and costs of patients with high-risk non–muscle-invasive bladder cancer with carcinoma in situ who are unresponsive to Bacillus Calmette-Guérin treatment: A real-world analysis using SEER-Medicare data
(323) Advancing the management of multiple myeloma via multiphase initiative centered on regional payer-provider forums
(324) Discovering current gaps in care and curating health plan best practices in the management of ER+/HER2- mBC: AMCP Market Insights program
(325) Treatment patterns and disease recurrence among patients with high-risk non–muscle-invasive bladder cancer with carcinoma in situ who are unresponsive to Bacillus Calmette-Guérin treatment: A real-world analysis using SEER-Medicare data
(326) Real-world treatment patterns, costs, and burden of illness in advanced or unresectable cutaneous melanoma following discontinuation of frontline PD-1 inhibitor therapy: A claims database analysis
(327) Healthcare resource utilization (HCRU) and costs among chemotherapy-naïve patients with metastatic castration‑resistant prostate cancer (mCRPC): a real-world assessment using data from the Veterans Affairs Healthcare System (VAHCS)
(328) Healthcare resource utilization (HCRU) and costs during second-line (2L) treatment for small-cell lung cancer (SCLC)
(329) A systematic review of economic evidence of advanced or metastatic gastroesophageal adenocarcinoma
(330) Budget impact of darolutamide + ADT for mCSPC from a United States payer perspective
(332) Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + d, and K + d in Relapsed/Refractory Multiple Myeloma (RRMM)
(333) Opportunities to improve care in HER2-positive gastrointestinal cancers: recommendations from payer and oncologist regional forums
(334) Nivolumab plus Ipilimumab as a First-line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer: a Cost-per-Outcome Analysis
(335) Patient characteristics, treatment patterns, and real-world outcomes among patients in the US with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors
(336) Safety of Combined Radioligand and Systemic Therapies in Neuroendocrine Tumors: A Systematic Review
(337) Evaluating Early-Onset Colorectal Cancer Incidence Trends and Geographic Disparities Among Adults Aged 20–50 in Michigan